Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-22-046291
Date:2022-08-17
Issuer: TURNING POINT THERAPEUTICS, INC. (TPTX)
Original Submission Date:

Reporting Person:

NICHOLSON GARRY A
C/O TURNING POINT THERAPEUTICS, INC.
10628 SCIENCE CENTER DRIVE, STE. 200 SAN DIEGO, CA 92121

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 59.11 2022-08-17 deemed execution date D 23,400 (d) 2030-01-21 common stock 23,400 $59.11 0 direct
STOCK OPTION (RIGHT TO BUY) 65.64 2022-08-17 deemed execution date D 8,500 (d) 2031-06-01 common stock 8,500 $65.64 0 direct
Footnotes
IDfootnote
f1 pursuant to the agreement and plan of merger (the "merger agreement"), dated as of june 2, 2022, by and among turning point therapeutics, inc. (the "issuer"), bristol-myers squibb company ("bms") and rhumba merger sub inc., a wholly owned subsidiary of bms ("purchaser"), on august 17, 2022, purchaser completed a tender offer for shares of common stock of the issuer (each, a "share") and thereafter merged with and into the issuer, with the issuer continuing as the surviving corporation and a wholly owned subsidiary of bms (the "merger").
f2 at the effective time of the merger, pursuant to the merger agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of shares subject to such option multiplied by (ii) the excess of (x) $76.00 per share over (y) the exercise price payable per share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
WhaleWisdom Logo

Elevate your investments